Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13000623 | 0.88 | — | — | |
| SCHEMBL13950015 | 0.88 | NPSR1 (0.43) | CARM1PRMT6PRMT8NPSR1PRMT1 | |
| SCHEMBL4393264 | 0.80 | NPSR1 (0.39) | NPSR1MC4RPAOXLMNACSNK2A2 | |
| SCHEMBL21636913 | 0.78 | NPSR1 (0.37) | CARM1PRMT6PRMT8NPSR1KDM4E | |
| SCHEMBL22918590 | 0.77 | ALDH1A1 (0.46) | CARM1PRMT6PRMT8NPSR1KDM4E | |
| SCHEMBL971887 | 0.77 | — | — | |
| SCHEMBL17338617 | 0.77 | — | — | |
| SCHEMBL22269041 | 0.76 | NPSR1 (0.36) | CARM1PRMT6PRMT8NPSR1 | |
| SCHEMBL22066263 | 0.76 | LMNA (0.38) | PRMT6NPSR1MC4RPAOXLMNA | |
| SCHEMBL2281455 | 0.76 | CARM1 (0.68) | CARM1PRMT6PRMT8PAOXPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-4137496-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| WO-2020210451-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2017093544-A1 | ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9084828-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| US-8816077-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100256056-A1 | ANALOGUES OF EXENDIN-4 AND EXENDIN-3 | IPSEN PHARMA S.A.S. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7604669-B2 | azo dyes, triazine dyes has good reproducibility and good all-round colorfastness properties, wet-fastness properties | HUNTSMAN INTERNATIONAL LLC (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080256726-A1 | azo dyes, triazine dyes has good reproducibility and good all-round colorfastness properties, wet-fastness properties | HUNTSMAN INTERNATIONAL LLC | 2008-10-23 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | CARM1 3965/4885PRMT6 2730/4885PRMT8 1840/4885 |
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | CARM1 4035/4885PRMT6 2859/4885PRMT8 1944/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | CARM1 895/4885PRMT6 408/4885PRMT8 605/4885 |
| US-20100256056-A1 | ANALOGUES OF EXENDIN-4 AND EXENDIN-3 | GLP1R, IAPP, MC4R | CARM1 3879/4885PRMT6 2670/4885PRMT8 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.